![Mike Casia](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Michael Casia has held positions as Chairman & Managing Director at Organon Canada, Inc. and Director at Biosimilars Canada.
Posizioni attive di Mike Casia
Società | Posizione | Inizio |
---|---|---|
Biosimilars Canada
![]() Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Direttore/Membro del Consiglio | - |
Organon Canada, Inc. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Biosimilars Canada
![]() Biosimilars Canada Miscellaneous Commercial ServicesCommercial Services Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association that provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines. Biosimilars Canada is based in Toronto, Canada. The member companies of Biosimilars Canada are involved in the development and marketing of biosimilar medicines. The organization advocates for policies that support the timely approval, reimbursement, market acceptance, and expanded use of biosimilar medicines. Health Canada evaluates all the information provided to confirm that the biosimilar and the reference biologic drug are similar and that there are no clinically meaningful differences in safety and efficacy between them. | Commercial Services |
Organon Canada, Inc. |
- Borsa valori
- Insiders
- Mike Casia